Investors currently view BGI Genomics as an underperforming company, largely influenced by its poor revenue growth over the past years. Its P/S ratio may tumble further if the company fails to improve its revenue growth, leading to further investor disappointment.
華大基因股票討論區
上週五,無錫 AppTec 股價下跌 20% 在香港並受到一個 10% 在中國大陸的限制。
其他 CRO 股票(包括 Medicilon)也在下跌。
$藥明生物(02269.HK)$ $藥明康德(02359.HK)$ $華大基因(300676.SZ)$ $華大智造(688114.SH)$ $美迪西(688202.SH)$ $諾和諾德(NVO.US)$ $恒生中國企業(02828.HK)$
暫無評論